menu
    • menu
    [{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Griffith University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Gonococcal Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech Biologics \/ Griffith University"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"LMTB Gonococcal Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech Biologics \/ Adjuvant Capital"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"LBT-SA7","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"LimmaTech Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"LimmaTech Biologics \/ Adjuvant Capital"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"S4V","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"LimmaTech Biologics \/ GSK"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"S4V","moa":"","graph1":"Technology","graph2":"Approved","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"LimmaTech Biologics \/ Valneva"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Shigella4V2","moa":"","graph1":"Technology","graph2":"Approved","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ LimmaTech Biologics","highestDevelopmentStatusID":"12","companyTruncated":"LimmaTech Biologics \/ LimmaTech Biologics"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Shigella4V2","moa":"","graph1":"Technology","graph2":"Approved","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ LimmaTech Biologics","highestDevelopmentStatusID":"12","companyTruncated":"LimmaTech Biologics \/ LimmaTech Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by LimmaTech Biologics

    Menu

    LimmaTech Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Shigella4V2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Valneva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valneva and LimmaTech Begin Phase 2b Study of Tetravalent Shigella Vaccine

                            Details : Shigella4V2 is a tetravalent bioconjugate vaccine consisting of the O-antigen polysaccharide of Shigella flexneri 2a, 3a, 6 & of S. sonnei, conjugated to the Pa exotoxin A protein as carrier protein.

                            Brand Name : Shigella4V2

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 13, 2024

                            Lead Product(s) : Shigella4V2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Valneva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Shigella4V2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Valneva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valneva and LimmaTech Receive Fast Track Status for Shigella Vaccine Candidate S4V

                            Details : Shigella4V (S4V) is the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, being investigated in 9 month old infants.

                            Brand Name : Shigella4V2

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : Shigella4V2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Valneva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S4V

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Valneva

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine

                            Details : The partnership of Limma with Valneva aims to advance the clinical development of Shigella4V (S4V), which is being evaluated in the mid-stage clinical trial studies for the treatment of Shigellosis.

                            Brand Name : Shigella4V

                            Molecule Type : Vaccine

                            Upfront Cash : $10.8 million

                            August 01, 2024

                            Lead Product(s) : S4V

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Valneva

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S4V

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LimmaTech Reports Positive Interim Phase I/II Data on Shigella Bioconjugate Vaccine S4V

                            Details : S4V (shigella4V) is a tetravalent bioconjugate vaccine candidate, which is currently being evaluated for the treatment shigellosis-an infectious disease.

                            Brand Name : Shigella4V

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : S4V

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LBT-SA7

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Adjuvant Capital

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LimmaTech Biologics Adds $3 Million in Series A Second Closing Totaling $40 Million

                            Details : The financing will advance company’s proprietary self-adjuvanting and multi-antigen vaccine technology platform and its vaccine pipeline, including LBT-SA7 (formerly IBT-V02).

                            Brand Name : LBT-SA7

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 01, 2024

                            Lead Product(s) : LBT-SA7

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Adjuvant Capital

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LMTB Gonococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Adjuvant Capital

                            Deal Size : $37.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LimmaTech Biologics Raises $37 Million Series A to Advance its Pipeline of Vaccines Against Multidrug-Resistan...

                            Details : The proceeds will advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates, including LMTB gonococcal vaccine, against bacterial infections, including programs addressing shigellosis and gonor...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 09, 2023

                            Lead Product(s) : LMTB Gonococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Adjuvant Capital

                            Deal Size : $37.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            LimmaTech Biologics

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gonococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Griffith University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine ...

                            Details : Vaccine technologies licensed from Griffith University will be used to develop novel vaccines for increasingly prevalent antibiotic resistant strains. LimmaTech will initially use technologies as well as its in-house expertise to develop the world’s fi...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Gonococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Griffith University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth